“Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada”, J of Skin, vol. 8, no. 1, p. s317, Jan. 2024, doi: 10.25251/skin.8.supp.317.